Took a seat on the Anthropic Board to influence the direction of AI in the pharmaceutical industry.

Aggressively using M&A to mitigate patent cliffs and protect market dominance in the allergy sector.

Acquired Accelergy for $2 billion to bolster its immunology pipeline and replace revenue from drugs with expiring patents.

The CEO presents a strong case that the company's focused strategy, strong competitive moat in areas like Radioligand Therapy, and deep integration of AI have created a more agile, innovative, and valuable business with clear growth drivers.

Listed on the watchlist of AI-focused pharmaceutical companies expected to 'outperform' for the rest of the year due to AI-driven efficiencies in drug development.

Benefits from a highly favorable regulatory environment where the FDA is reducing barriers and accelerating approvals for cell and gene therapies, including CAR-T.

Cited as an example of an incumbent that struggles with internal innovation but can succeed by 'renting' innovation from startups through partnerships, licensing, and acquisitions.

Has a historical connection to the origins of psychedelic research (LSD) through its acquisition of Sandoz. While not currently a 'psychedelic stock,' this history is noted as relevant to the entire sector's regulatory landscape.

Access to Isomorphic Labs' AI drug discovery engine provides a major potential competitive advantage and could accelerate R&D. Positive news from preclinical trials in 2025 could be a significant stock driver.

Is set to acquire Tourmaline Bio, participating in a broader surge in M&A activity which can be a sign of economic confidence.